These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 2162294)
1. Systemic and coronary haemodynamics and pharmacodynamics of enalapril and enalaprilat in congestive heart failure. Chatterjee K; De Marco T Drugs; 1990; 39 Suppl 4():29-40; discussion 41-2. PubMed ID: 2162294 [TBL] [Abstract][Full Text] [Related]
2. Enalaprilat, a new parenteral angiotensin-converting enzyme inhibitor: rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure. De Marco T; Daly PA; Liu M; Kayser S; Parmley WW; Chatterjee K J Am Coll Cardiol; 1987 May; 9(5):1131-8. PubMed ID: 3033043 [TBL] [Abstract][Full Text] [Related]
3. The kinetic profiles of enalapril and enalaprilat and their possible developmental changes in pediatric patients with congestive heart failure. Nakamura H; Ishii M; Sugimura T; Chiba K; Kato H; Ishizaki T Clin Pharmacol Ther; 1994 Aug; 56(2):160-8. PubMed ID: 8062492 [TBL] [Abstract][Full Text] [Related]
4. Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure. Evans MA; Burnett JC; Redfield MM J Am Coll Cardiol; 1995 May; 25(6):1445-50. PubMed ID: 7722147 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension. Schwartz JB; Taylor A; Abernethy D; O'Meara M; Farmer J; Young J; Nelson E; Pool J; Mitchell JR J Cardiovasc Pharmacol; 1985; 7(4):767-76. PubMed ID: 2410720 [TBL] [Abstract][Full Text] [Related]
6. Increase in vasoactive intestinal polypeptides (VIP) by the angiotensin converting enzyme (ACE) inhibitor lisinopril in congestive heart failure. Relation to haemodynamic and hormonal changes. Woie L; Dickstein K; Kaada B Gen Pharmacol; 1987; 18(6):577-87. PubMed ID: 2822521 [TBL] [Abstract][Full Text] [Related]
7. Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses. Gardner SY; Atkins CE; Sams RA; Schwabenton AB; Papich MG J Vet Intern Med; 2004; 18(2):231-7. PubMed ID: 15058776 [TBL] [Abstract][Full Text] [Related]
8. Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors. Sigurdsson A Blood Press Suppl; 1995; 1():1-45. PubMed ID: 7599749 [TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review. Kubo SH; Cody RJ Clin Pharmacokinet; 1985; 10(5):377-91. PubMed ID: 2994938 [TBL] [Abstract][Full Text] [Related]
10. Clinical and hemodynamic experience with enalapril in congestive heart failure. Cody RJ Am J Cardiol; 1985 Jan; 55(2):36A-40A. PubMed ID: 2981464 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses. Gómez-Díez M; Muñoz A; Caballero JM; Riber C; Castejón F; Serrano-Rodríguez JM Res Vet Sci; 2014 Aug; 97(1):105-10. PubMed ID: 24972864 [TBL] [Abstract][Full Text] [Related]
12. Angiotensin II-mediated vasoconstriction in chronic congestive heart failure, and response to converting enzyme inhibition. Cody RJ Am J Med; 1984 Aug; 77(2A):71-7. PubMed ID: 6089559 [TBL] [Abstract][Full Text] [Related]
13. Clinical studies of enalapril treatment for patients with severe congestive heart failure. Sato T; Takeshi M; Yamamoto A Jpn Circ J; 1992 Jan; 56(1):35-45. PubMed ID: 1538575 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. Greenbaum R; Zucchelli P; Caspi A; Nouriel H; Paz R; Sclarovsky S; O'Grady P; Yee KF; Liao WC; Mangold B Br J Clin Pharmacol; 2000 Jan; 49(1):23-31. PubMed ID: 10606834 [TBL] [Abstract][Full Text] [Related]
16. Effect of cimetidine on the pharmacokinetics and pharmacodynamics of enalapril in normal volunteers. Ishizaki T; Baba T; Murabayashi S; Kubota K; Hara K; Kurimoto F J Cardiovasc Pharmacol; 1988; 12(5):512-9. PubMed ID: 2468049 [TBL] [Abstract][Full Text] [Related]
17. A randomized cross-over study of enalapril in congestive heart failure: haemodynamic and hormonal effects during rest and exercise. Mulligan IP; Fraser AG; Tirlapur V; Lewis MJ; Newcombe RG; Henderson AH Eur J Clin Pharmacol; 1988; 34(4):323-31. PubMed ID: 2841136 [TBL] [Abstract][Full Text] [Related]
18. Enalapril in congestive heart failure: acute hemodynamic and neurohumoral evaluation and short-term follow-up. Lin M; Chiang HT; Chang MS; Kong CW; Wang SP; Chiang BN Zhonghua Yi Xue Za Zhi (Taipei); 1991 Jul; 48(1):31-40. PubMed ID: 1679372 [TBL] [Abstract][Full Text] [Related]
19. Plasma concentrations of angiotensin II and aldosterone during acute left ventricular failure in the dog. Effect of converting enzyme inhibition. Hall C; Karlberg BE Res Exp Med (Berl); 1986; 186(5):387-95. PubMed ID: 3025983 [TBL] [Abstract][Full Text] [Related]
20. Conceptual and therapeutic approaches to inhibition of the renin-angiotensin system in chronic heart failure. Cody RJ J Cardiovasc Pharmacol; 1986; 8 Suppl 1():S58-65. PubMed ID: 2422494 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]